Nanovibronix (NASDAQ:FEED) Insider Sells $144,900.00 in Stock

Nanovibronix, Inc. (NASDAQ:FEED) insider Christian Michael Glibert sold 210,000 shares of the stock in a transaction that occurred on Monday, June 22nd. The stock was sold at an average price of $0.69, for a total value of $144,900.00. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.

Nanovibronix Stock Performance

FEED stock traded up $0.03 on Monday, reaching $0.70. 398,578 shares of the company’s stock were exchanged, compared to its average volume of 7,079,931. The company has a fifty day moving average of $1.12. The company has a market cap of $4.26 million, a price-to-earnings ratio of -0.08 and a beta of 1.52. Nanovibronix, Inc. has a twelve month low of $0.63 and a twelve month high of $17.40.

Nanovibronix (NASDAQ:FEED) last released its earnings results on Monday, May 18th. The company reported ($6.88) EPS for the quarter. The business had revenue of $0.65 million during the quarter. Nanovibronix had a negative net margin of 923.20% and a negative return on equity of 54.25%.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on the company. Weiss Ratings restated a “sell (e+)” rating on shares of Nanovibronix in a report on Friday, April 24th. Wall Street Zen raised Nanovibronix from a “strong sell” rating to a “sell” rating in a report on Tuesday, April 28th. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company presently has a consensus rating of “Sell”.

Nanovibronix Company Profile

Nanovibronix (NASDAQ: FEED) is a medical device company focused on the development and commercialization of non‑invasive therapeutic ultrasound technologies for clinical and consumer healthcare applications. The company’s product portfolio centers on wearable ultrasound devices designed to deliver low‑intensity acoustic energy to soft tissue with the objective of promoting wound healing and reducing pain. Nanovibronix positions its technology as an alternative or adjunct to conventional wound‑care and analgesic therapies, aiming to address chronic and acute conditions that are managed in both outpatient and home settings.

The company concentrates its commercial efforts on supplying hospitals, wound‑care clinics, long‑term care facilities and patients requiring home‑based therapies.